HC Wainwright Issues Optimistic Outlook for OKUR Earnings

OnKure Therapeutics, Inc. (NASDAQ:OKUR) – Research analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for shares of OnKure Therapeutics in a note issued to investors on Monday, March 16th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($1.05) for the quarter, up from their prior forecast of ($1.15). HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for OnKure Therapeutics’ Q2 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.88) EPS and FY2026 earnings at ($3.66) EPS.

A number of other brokerages also recently weighed in on OKUR. Weiss Ratings reiterated a “sell (d-)” rating on shares of OnKure Therapeutics in a report on Monday, December 22nd. Wall Street Zen upgraded shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $27.00.

OnKure Therapeutics Stock Performance

OKUR opened at $4.02 on Wednesday. The company has a market capitalization of $54.46 million, a P/E ratio of -0.91 and a beta of 0.45. OnKure Therapeutics has a 1-year low of $1.70 and a 1-year high of $5.28. The company has a 50-day moving average of $2.88 and a 200-day moving average of $2.89.

OnKure Therapeutics (NASDAQ:OKUR) last announced its earnings results on Monday, March 9th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.16.

Institutional Investors Weigh In On OnKure Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in OnKure Therapeutics during the second quarter valued at about $25,000. Jane Street Group LLC purchased a new stake in OnKure Therapeutics in the 4th quarter worth approximately $56,000. Rangeley Capital LLC acquired a new stake in OnKure Therapeutics during the second quarter valued at $71,000. Barclays PLC lifted its holdings in shares of OnKure Therapeutics by 4,286.8% during the 4th quarter. Barclays PLC now owns 27,242 shares of the company’s stock valued at $79,000 after buying an additional 26,621 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its stake in OnKure Therapeutics by 172.1% in the third quarter. GSA Capital Partners LLP now owns 59,224 shares of the company’s stock valued at $163,000 after acquiring an additional 37,459 shares during the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.